Product Overview
Composition
1 tablet contains: Active substance - ethylmethylhydroxypyridine succinate in terms of 100% substance - 0.125 g. Excipients (tablet core): Kaolin - 0.00247 g, Sodium carboxymethyl starch - 0.01258 g, Microcrystalline cellulose - 0.1135 g, Povidone - 0.0134 g, Talc - 0.0053 g, Calcium stearate - 0.00275 g. Excipients (shell): Hypromellose - 0.00495 g, Macrogol - 0.00128 g, Titanium dioxide - 0.00165 g, Talc - 0.00037 g.
pharmachologic effect
Mexiprim belongs to heteroaromatic antioxidants.
Has a wide range of pharmacological activity: increases the body's resistance to stress, exhibits anxiolytic effect, not accompanied by a muscle relaxant effect;
possesses nootropic properties, prevents and reduces learning and memory disorders arising from aging and exposure to various pathogenic factors; has an anticonvulsant effect;
exhibits antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol.
The drug improves the metabolism of brain tissues and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation.
It stabilizes the membrane structures of blood cells (erythrocytes and platelets). It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.
The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action.
It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity.
Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA,
acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, transport neurotransmitters and improve synaptic transmission.
Mexiprim increases the content of dopamine in the brain.
It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.
Active ingredients
Indications
- anxiety disorders in neurotic and neurosis-like states;
- vegetative-vascular dystonia;
- mild cognitive disorders of various origins (with psychoorganic syndrome and asthenic disorders caused by acute and chronic disorders of cerebral circulation, craniocerebral trauma, neuroinfections and intoxications, senile and atrophic processes);
- memory disorders and intellectual disability in the elderly;
- exposure to extreme (stress) factors;
- alcohol withdrawal syndrome with a predominance of neurosis-like and vegetative-vascular disorders.
Application during pregnancy and lactation
Currently, the possibility and safety of using Mexiprim during pregnancy and lactation has not been sufficiently studied, therefore, the use of the drug in this category of patients is contraindicated.
Contraindications
- Increased individual sensitivity to Mexiprim;
- acute disorders of liver and kidney function;
- childhood;
- pregnancy;
- breast-feeding.
Side effects
The appearance of individual side reactions is possible: nausea and dryness of the oral mucosa, drowsiness, allergic reactions.
Interaction
Compatible with psychotropic drugs. Strengthens the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa), reduces the toxic effect of ethyl alcohol.
How to take, course of administration and dosage
Mexiprim is prescribed internally.
The applied therapeutic doses and the duration of treatment are determined by the sensitivity of patients to the drug.
Treatment is started with a dose of 0.25-0.5 g; the average daily dose is 0.25-0.5 g, the maximum daily dose is 0.8 g. The daily dose of the drug is divided into 2-3 doses during the day.
For the treatment of patients with anxiety disorders, vegetative-vascular dysfunctions and cognitive impairments, Mexiprim is used for 2-6 weeks.
When relieving alcohol withdrawal syndrome, Mexiprim is used for 5-7 days.
The course therapy with Meksiprim is completed gradually, reducing the dose of the drug within 2-3 days.
Overdose
Symptoms:
sleep disturbance (insomnia, in some cases - drowsiness).
Treatment:
usually not required - symptoms disappear on their own within 24 hours. In severe cases of insomnia, it is recommended to take nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.
Appointment
Description
Tablets are round, biconvex, film-coated, from white to white with a creamy shade, at a break - from white to white with a grayish, or yellowish, or creamy shade.
Functional features
Mexiprim is rapidly absorbed from the gastrointestinal tract with a half-absorption period of 0.08-0.1 hours.
The time to reach the maximum concentration in blood plasma is 0.46-0.5 hours.
The maximum plasma concentration of Mexiprim is in the range from 50 to 100 ng / ml.
The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively.
Mexiprim in the human body is extensively metabolized to form its glucuronoconjugated product.
On average, 0.3% of the unchanged drug and 50% in the form of glucuronoconjugate of the administered dose are excreted in the urine over 12 hours.
The most intense Mexiprim and its glucuronoconjugate are excreted during the first 4 hours after taking the drug.
Indicators of excretion in the urine of Mexiprim and its conjugated metabolite have significant individual variability.
Equipment
Special instructions
The degree of restrictions is determined by the individual tolerance of the drug. During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Release form
Tablets, film-coated, 125 mg. On 10 tablets in a blister strip of a film of polyvinyl chloride and aluminum foil. 1, 2, 3, 4 or 6 blister packs, together with instructions for use, are placed in a cardboard box.
